High-Level Expression of Wild-Type p53 in Melanoma Cells is Frequently Associated with Inactivity in p53 Reporter Gene Assays

Roland Houben¹, Sonja Hesbacher¹, Corinna P. Schmid¹, Claudia S. Kauczok¹, Ulrike Flohr¹, Sebastian Haferkamp¹, Cornelia S. L. Müller³, David Schrama¹,4, Jörg Wischhusen², Jürgen C. Becker⁴*

¹Department of Dermatology, University Hospital Würzburg, Würzburg, Germany, ²Department for Obstetrics and Gynecology, University of Würzburg, Würzburg, Germany, ³Department of Dermatology, University of Saarland, Homburg/Saar, Germany, ⁴Department of General Dermatology, Medical University of Graz, Graz, Austria

Abstract

**Background:** Inactivation of the p53 pathway that controls cell cycle progression, apoptosis and senescence, has been proposed to occur in virtually all human tumors and p53 is the protein most frequently mutated in human cancer. However, the mutational status of p53 in melanoma is still controversial; to clarify this notion we analysed the largest series of melanoma samples reported to date.

**Methodology/Principal Findings:** Immunohistochemical analysis of more than 180 melanoma specimens demonstrated that high levels of p53 are expressed in the vast majority of cases. Subsequent sequencing of the p53 exons 5–8, however, revealed only in one case the presence of a mutation. Nevertheless, by means of two different p53 reporter constructs we demonstrate transcriptional inactivity of wild type p53 in 6 out of 10 melanoma cell lines; the 4 other p53 wild type melanoma cell lines exhibit p53 reporter gene activity, which can be blocked by shRNA knock down of p53.

**Conclusions/Significance:** In melanomas expressing high levels of wild type p53 this tumor suppressor is frequently inactivated at transcriptional level.

---

Introduction

p53, the “guardian of the genome”, is a transcription factor that can bind to promoter regions of hundreds of genes where it either activates or suppresses gene expression [1]. Thereby, p53 serves as a tumor suppressor by inducing cell cycle arrest, apoptosis, senescence and DNA repair [2]. In normal cells, p53 is frequently undetectable due to fast ubiquitination by mdm-2 and subsequent proteasomal degradation [3]. However, upon DNA damage and several other stresses, including oncogenic stress, the amount of p53 is increased due to disruption of its degradation [4,5]. Notably, inactivation of p53 is one of the characteristics of cancer. Indeed, p53 has a wide spectrum of mutation types and p53 is found mutated in approximately half of all tumors [6]. Most of these aberrations are missense mutations in the central DNA binding domain disrupting the transcriptional capability and conferring different degrees of dominance over co-expressed wild-type p53 [7]. Alternatively, impairment of the p53 response to oncogenic stress has been reported which is mediated via increased degradation by viral proteins or mdm-2 overexpression [8,9]. Moreover, p53 induction may be affected for example by loss of p14ARF [10]. On a post-translational level, the transcriptionally activity of p53 can also be impaired by sequestration in the cytosol [11], by competition for DNA-binding sites by ΔNp73 [12] or functional antagonism with iASPP [13].

Recently, p53 has been suggested to be a major player suppressing progression from nevi to melanoma [14]. Studies on the frequency of p53 mutations in melanoma, however, reported relatively low but quite divergent numbers ranging from 0 to 30% [15–20]. To address this controversy we here evaluated a large series of more than 180 melanoma samples for p53 protein expression and genetic p53 mutations. Although p53 is generally expressed in melanoma tissues it harbours only very rarely mutations. In contrast, in 4 of 14 melanoma cell lines p53 was found to be mutant. Notably, in melanoma cell lines which have preserved the p53 wild-type geno/phenotype observed in situ, we demonstrate transcriptional inactivity of the protein in 6 out of 10 cell lines suggesting active silencing as the mode of p53 inactivation in melanoma.

Results and Discussion

Expression of p53 in melanoma

Many tumors accumulate mutant p53 protein which is explained by a lack of p53-dependent Mdm-2 induction leading
to decreased proteasomal degradation [3]. Immunohistochemical analysis of 185 melanoma samples demonstrated that in the majority of tumors high levels of p53 are expressed in a considerable proportion of the tumor cells (Figure 1 A and B). Moreover, we observed an increase in p53 expression from primary to metastatic tumors (Figure 1B), thereby confirming previous reports [21].

Absence of p53 mutation in melanoma

p53 mutation frequencies of 21, 24 or 29% have been described for melanoma tissues and short term melanoma cell cultures [17–19]. Prompted by these reports and the finding that p53 was highly expressed in situ, we started to analyze genomic DNA from a series of 206 paraffin-embedded melanoma tissues by nested PCR amplification and direct sequencing of the p53 exons 5–8; these exons harbour 95% of the known p53 mutations [10]. All four, three, two or only one exon were successfully amplified for 128, 34, 32 or 12 samples, respectively. In 26% of the samples, we observed irreproducible PCR artefacts which pretended possible mutations (Figure 2). However, a reproducible amino acid substitution (P278R; C833G; heterozygous; GenBank accession number: 573759) was only observed in one case (Figure 2). We do not know whether sequencing results in studies observing higher p53 mutation rates were controlled for reproducibility but reported high frequencies of silent mutations as well as double and triple mutations in one exon may be indicative of false positives [18,19]. Furthermore, formalin-fixed paraffin-embedded material as used in these studies (like in ours) is notorious for generating PCR artefacts [22]. Based on carefully reproduced sequencing results in this - to the best of our knowledge - largest series studied to date, we now confirm previous reports describing a virtual absence of p53 mutations in melanoma tissues [13,16,20]. However, we have to admit that there was a considerable fraction of 78 samples for which we failed to amplify all 4 exons. Thus, we do not know the complete sequence of the p53 mutation hot spot region in this fraction of specimens. All primer binding sites, however, were located in exon-flanking introns, thus, failure of amplification does not indicate an altered coding sequence. Moreover, as we could detect p53 expression in virtually all corresponding tissues, inability of PCR amplification cannot be due to loss of both p53 alleles. Most likely, failure of amplification, is simply due to limited quality of the gDNA extracted from the formalin-fixed and paraffin-embedded tissues. This is further substantiated by the fact that for many of the respective DNAs not only amplification of more than one p53 exon but also amplification from other genes like BRAF and NRAS failed.

p53 mutations in melanoma cell lines

Notably, several of the previous studies on p53 mutations were carried out in melanoma cell lines. Thus, we analysed the mutational status of p53 in 14 melanoma cell lines by sequencing all coding exons of p53. 4 of the 14 cell lines, i.e. BLM, IF-6, Mel2a and FM55, harboured p53 mutations (Figure 3; GenBank accession numbers 573755–573758). All of the mutations have been described to be inactivating (http://www-p53.iarc.fr). Interestingly, all four sequences lacked the corresponding wild type signal indicating either homozygous mutation or more probably loss of heterozygosity at the p53 locus. In line with this, FM55 cells, where the mutation leads to a premature stop codon, express only the truncated p53 protein indicated by increased mobility in gel electrophoresis (Figure 3). Hence under culture

![Figure 1. p53 expression in melanoma tissues. (A) Immunohistochemical detection of p53 in a primary melanoma. (B) 104 primary cutaneous and 81 metastatic melanoma samples were stained for p53. The percentage of positively stained tumor cells is given as bar graph. doi:10.1371/journal.pone.0022096.g001](image)

![Figure 2. Reproducibility of p53 sequencing. Sequencing chromatograms depicting the only reproducible p53 mutation and an example of an apparent mutation which could not be reproduced in an independent PCR amplification from the same sample. doi:10.1371/journal.pone.0022096.g002](image)
conditions melanoma cells tend to acquire inactivating p53 mutations although in situ mutant p53 is not favoured [15].

Absence of p53 reporter gene activity in 6 out of 10 wt p53 melanoma cell lines

Most of the above-described melanoma cell lines express high levels of p53 which are comparable to those found in melanoma cells in situ. To understand why melanoma cells tolerate high levels of wild type p53 expression we addressed the pertinent question whether p53 is transcriptionally active in these cells. To this end, in a first set of experiments 10 of the melanoma cell lines described above were stably transfected with a PathDetect® reporter plasmid coding for luciferase under the control of a p53 enhancer element. As expected, the 4 melanoma cell lines harbouring inactivating p53 mutations did not show p53-dependent luciferase expression (Figure 3). Surprisingly, however, among the 6 cell lines with wild type p53 p53-dependent luciferase expression which could be abolished upon shRNA knock down of p53 was only observed in FM88 and MelJuso cells (Figure 3). The presence of the luciferase DNA in the genome was confirmed by real time PCR for all 10 cell lines (in Figure 3 the relative copy numbers are given on top of the figure) and the functionality of the luciferase reporter could be demonstrated in 8 of the cell lines as luciferase expression was inducible upon transient ectopic expression of p53 (data not shown). Thus, in 4 out of 6 cell lines which reflect the in situ p53 status, no p53-dependent luciferase expression could be detected (Figure 3).

Since it is known that different p53 responsive elements are targeted differentially by p53 depending on the cellular and environmental

Figure 3. Functional inactivity in 4 out of 6 melanoma cell lines expressing wild type p53 measured by the p53 reporter construct PathDetect®. The p53 reporter construct PathDetect® encoding luciferase under the control of a p53 responsive element (14×TGCTGGACTGCTGG) was transfected into the indicated melanoma cell lines. Following selection for a co-transfected puromycin resistance integration of the luciferase gene was confirmed by real time PCR and the relative copy numbers are indicated (top row). The cells were then infected with lentiviral supernatants carrying the shRNA expression construct KH1 containing either a scrambled or a sequence targeting p53 [41]. On Day 4 following infection the cells were harvested and lysates were subjected to a luciferase assay (upper part) or were analysed for expression of the indicated proteins by western blot (lower part). Sequence analysis of all p53 coding exons revealed that four cell lines carried the indicated p53 amino acid substitutions.

doi:10.1371/journal.pone.0022096.g003
background [23] we tested a second reporter with a different p53 response element. As we, furthermore, aimed to analyze primary melanocytes as an untransformed control we used the lentiviral pGreenFire p53 reporter, which allowed efficient transduction of melanocytes. In addition to four of the p53 wild type melanoma cell lines analyzed by the PathDetect reporter in the first series of experiments, human epidermal melanocytes (HEM) as well as four short term melanoma cell lines carrying wild type p53 (WuMel) were analyzed in this set of experiments. The results obtained with the PathDetect p53 reporter were definitely reproduced with the pGreenFire p53 reporter for FM88, MelJuso, Skmel28 and M26 (Figure 4). Out of the four WuMel cell lines WuMel48 and 74a - which were proliferating only very slowly in vitro - displayed high, p53 shRNA repressible, p53 reporter gene activity, although p53 was expressed at relatively low levels (Figure 4). In contrast, WuMel45 and 49 were characterized by lack of p53 transcriptional activity in the presence of high levels of wild type p53 (Figure 4). A high level p53 transcriptional activity - almost comparable to those observed in the melanoma cells - measured in HEMs suggests that tolerating such p53 activities may be an intrinsic feature of melanocytic cells.

The pGreenFire vector contains luciferase and GFP which are both expressed under the control of a p53 responsive element. Results obtained for GFP fluorescence analyzed by flow cytometry (mean fluorescence intensity) and luciferase assays were highly concordant, indeed (Figure 5 A and B). Moreover, as flow cytometry allows analysis on a single cell level, we could exclude that high reporter gene activity in melanocytes or in the respective melanoma cell lines represents an average of high and low p53 activity in different sub-populations (Figure 5 B).

In order to rank the levels of p53 dependent luciferase/GFP expression with regard to the growth-inhibitory function of p53, we treated the cells with Nutlin-3a, a specific inhibitor of the p53 ubiquitinase mdm-2. This intervention induced both moderate increases in p53 expression (Figure 5 C) and p53 transcriptional activity (Figure 5 A and B); this moderate increase, however, was associated with a clear cut cell cycle arrest for HEMs, FM88 and MelJuso (Figure 5D). In contrast S-phase entry was not impaired in the low level p53 activity melanoma cell lines (Figure 5 D). In this context, SKmel28, WuMel45 and WuMel49 did not show an increase in p53 expression suggesting that mdm-2 does not restrict p53 expression in these cell lines (Figure 5C).

---

**Figure 4. Functional inactivity in 4 out of 8 melanoma cell lines expressing wild type p53 measured by the p53 reporter construct pGreenFire.** Human epidermal melanocytes and the indicated melanoma cell lines were stably transduced with a lentiviral pGreenFire reporter construct encoding luciferase and GFP under the control of a p53 responsive element (4 × CGACATGCCCGGGCATGT). The cells were then infected with lentiviral supernatants carrying the shRNA expression construct KH1 containing either a scrambled or a sequence targeting p53 [41]. On Day 4 following infection total cell lysates were analysed for p53 expression by immunoblotting (lower part). Equal loading was controlled by Ponceau S staining of the blot. In the upper part the corresponding luciferase activity is depicted, normalized to the relative luciferase load of the cell lines determined by Real time PCR.

doi:10.1371/journal.pone.0022096.g004
In summary, our data demonstrate that p53 mutations are at best a rare event in melanoma in situ; still, strong protein expression in melanoma tissue indicates aberrations of p53 activity. Accordingly, we demonstrate functional inactivation of p53 in a considerable proportion (60%) of melanoma cell lines characterized by wild type p53. This notion is corroborated by a recent report of a gene expression profiling study which demonstrates that p53 target genes are differentially expressed in melanomas compared with nevi, strongly suggesting a dysfunctional p53 [24]. Moreover, our results are consistent with the reported UV response of melanoma cell lines [25]; i.e. despite p53 target gene induction, p53 DNA-binding activity was absent in melanoma cells with wild type p53. Interestingly, the authors further reported that p53 target genes were similarly induced in cells with mutant p53, thereby suggesting a comparable functional activity of the DNA damage pathway upon UV-irradiation in melanoma cells with wild type and mutated p53.

Future studies will be required to determine the mechanisms which lead to transcriptional inactivity of wild type p53 in melanomas. Possibly it involves proteins known to inhibit p53 like iASPP, APlp73, YB-1 or Parc through direct interaction [11–13,26]. Alternatively, silencing might be achieved by posttranslational modifications. In this respect phosphorylation, acetylation, methylation, sumoylation and neddylation have been identified to impact p53 transcriptional activity [27]. Especially acetylation has been shown to alter p53 target specificity [28]. Recently Satyamoorthy and colleagues reported that impairment in DNA damage induced phosphorylation of p53 on serine-376 may contribute to radioresistance of melanoma cells [29]. Moreover, the preservation and increase of wild type p53 expression during melanoma progression may be indicative of a tumor promoting function of functionally silenced wild type p53. Therefore, cytoplasmic functions of transcriptionally inactive p53 should be analysed since they may either limit or promote tumor growth [30,31].

Materials and Methods

Ethics Statement

Written informed consent was obtained from all patients prior to any of these measures and the study was performed in adherence to the Declaration of Helsinki Principles. The medical ethical committee of the Universitätsklinik Würzburg approved all described studies. Generation of melanoma cell lines after written consent from the patients was approved by the Institutional Review Board of Würzburg University Hospital (Ethikkommission der Medizinischen Fakultät der Universität Würzburg; sequential study number 123/08_ff).

Tumor material and p53 sequencing. Paraffin-embedded tumor samples from primary and metastatic melanomas were obtained by surgical excision. All tumors had undergone routine histology for diagnosis. The three immediately following slides from the blocks were used for DNA extraction and the following slides were used to confirm the presence of the lesion and for immunohistochemistry.

Sequence analysis of p53 exons 5 to 8

Prior to DNA extraction adjacent normal tissue was macroscopically dissected. For sequencing (SeqLab; Göttingen, Germany) the p53 exons 5, 6, 7 and 8 were amplified with BioTherm
The second p53 reporter construct was the pGreenFire lentiviral vector (SBI, Mountain View, Canada) which codes for a puromycin resistance and for green fluorescent protein (GFP) as well as luciferase under the control of a different p53 responsive element (4× CGACATGCCCAGCCCATG). Knock down of p53 protein expression was achieved by a lentiviral shRNA expression construct KH1 containing either a scrambled or a sequence targeting p53 [41]. Infectious viruses were raised by transfecting HEK299T [42] cells with the pGreenFire construct or the respective KH1 vector and the helper constructs p59, p60 and p61. Two days following transfection, virus supernatants were harvested and filtered through 0.45 μm pore size filters. For infection, virus-containing supernatants were supplemented with 4 μg/ml polybrene and then added to the target cells overnight. Then medium was changed and the cells were cultured for 3 more days prior to subjecting lysates of the cells to further analysis. Pure populations carrying the pGreenFire reporter were selected by culturing the cells in the presence of puromycin.

Real time PCR
To quantitate the relative presence of the reporter constructs in the transfected or infected cells a real time PCR assay for luciferase was applied. Genomic DNA derived from the cell lines was analyzed using TaqMan technology with primers (forward: 5’- TTG GCA GAA GCT ATG AAA CG -3’; reverse: 5’- GCA ACT GCA ACT CCG ATA AA -3’) and a respective probe (TP: FAM-CGC CCA ACA CCG GCA TAA AGA -Tma), by normalization to the highly repetitive DNA elements LINE1 - for which the copy number even in cancer cells is largely constant - a relative quantification of the samples could be calculated by the ΔΔCt method.

p53 reporter gene assay
Following 2 washes with PBS, triplicates of infected cells were harvested by adding lysis buffer (10 mM NaCl, 8 mM tricine (pH 7.8), 0.4 mM EDTA, 1 mM DTT and 0.2% Triton X-100). After shaking for 20 min at room temperature, the lysates were frozen and stored at −20°C overnight. Upon thawing, the lysates were centrifuged and 50 μl of supernatant was transferred to a luminometer plate and luciferase activity was measured in an automatic injection of a luciferase buffer as previously described [43]. Flow cytometry to monitor GFP expression in pGreenFire transduced cells was performed on a FACSCanto (BD, Heidelberg, Germany).

Western blot analysis
Cells were lysed in Laemmli buffer and proteins were resolved by SDS-polyacrylamid gel electrophoresis and transferred to nitrocellulose membranes. Following blocking for 1 h with PBS containing 0.05% Tween 20 and 5% powdered skim milk, blots were incubated overnight with the primary antibody, washed three times with PBS with 0.03% Tween 20, and then incubated with a peroxide coupled secondary antibody. Following extensive washing, the bands were detected using a chemoluminescence detection kit (Roche Diagnostics, Mannheim, Germany). Antibodies to p53 (D-01) (Santa Cruz, Heidelberg, Germany) and β-tubulin (Sigma, Ottobrunn, Germany) were used.

Cell cycle analysis
Cells were harvested and resuspended in 0.5 ml PBS supplemented with 1% fetal calf serum. Five ml of ice-cold EtOH was added, followed by an over night incubation at 4°C. The fixed cells were pelleted and resuspended in 1 ml PBS supplemented with 1% fetal calf serum, 0.05 mg/ml propidium iodide, and...
0.1 mg/ml RNase A. Following a 1-hour incubation at 37°C, analysis of the cellular DNA content was performed on a FACSCanto flow cytometer.

Acknowledgements

We are grateful to Monique Verhaegen who provided the lentiviral KH1-p53 and KH1-scrambled shRNA constructs and to Eva-Maria Stuhl for technical assistance.

References

1. Song H, Xu Y (2007) Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways. Cell Cycle 6: 1570–1573.
2. Green DR, Chiu PK (2006) p53 and metabolism: Inside the TIGAR. Cell 126: 36–32.
3. Blagosklonny MV (1997) Loss of function and p53 protein stabilization. Oncogene 15: 1889–1893.
4. Lavin MF, Gueven N (2006) The complexity of p53 stabilization and activation. Cell Death Differ 13: 941–950.
5. Sherr CJ (2006) Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663–673.
6. Roemer K (1999) Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators. Biol Chem 380: 479–487.
7. van Oijen MG, Snoeck PG (2000) Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 6: 2138–2145.
8. Crook T, Tied J, Vousden KH (1991) Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67: 547–556.
9. Michael D, Oren M (2002) The p53 and Mdm2 families in cancer. Curri Opin Genet Dev 12: 53–59.
10. Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2: 594–604.
11. Nikolaeff AY, Li M, Puskar N, Qin J, Gu W (2003) Parc: a cytoplasmic anchor for p53. Cell 112: 29–40.
12. Groth TJ, Novak U,Maisse C, Barcaroli D, Luthi AU, et al. (2001) Human delta iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Cell Death Differ 8: 1213–1223.
13. Bergamaschi D, Samuels Y, O’Neil NJ, Trigante G, Crook T, et al. (2003) iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33: 162–167.
14. Terrzian T, Torchia GC, Dai D, Robinson SE, Murao K, et al. (2010) p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res 23: 781–794.
15. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, et al. (1994) Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 4: 35–45.
16. Castrensa JS, Rubino MP, Vazquez JJ, Idearte M, Sober AJ, et al. (1993) Lack of allelic deletions and point mutations as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 55: 362–365.
17. Danzotti M, Oggioni M, Ramaazi T, Vassari L, Campi V, et al. (2004) BRAF alterations are associated with complex prognostic profiles in malignant melanoma. Oncogene 25: 5968–5977.
18. Ragnarsson-Odling BK, Karsberg S, Platz A, Ringborg UK (1999) p53 alterations are associated with complex prognostic profiles in malignant melanoma. J Am Acad Dermatol 40: 543–546.
19. Zerp SF, van Ekas A, Peltenburg LT, Schrier PI (2002) p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomasogenesis. Br J Cancer 79: 921–928.
20. Papp T, Jafari M, Schlimm D (1996) Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions. J Cancer Res Clin Oncol 122: 481–488.
21. Box NF, Jiang T (2000) The role of p53 in pigmentation, tanning, and melanoma. Pigment Cell Melanoma Res 13: 525–533.
22. Kern SE, Winter JM (2006) Elegance, silence and nonsense in the mutations literature for solid tumors. Cancer Biol Ther 5: 349–359.
23. Ayday Y, Oren M (2007) Living with p53, dying of p53. Cell 130: 597–600.
24. Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, et al. (2009) The Role of BRAF Mutation and p53 Inactivation during Transformation of a Subpopulation of Primary Human Melanocytes. Am J Pathol.
25. Haapajärvi T, Pitkanen K, Laiho M (1999) Human melanoma cell line UV responses show independence of p53 function. Cell Growth Differ 10: 163–171.
26. Horner C, Knight DA, Hananeia L, Sherad P, Risk J, et al. (2005) Y-box factor YBL predicts p53 apoptotic function. Oncogene 24: 8314–8325.
27. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137: 609–622.
28. Tang Y, Luo J, Zhang W, Gu W (2006) Tip60-dependent Acetylation of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis. Molecular Cell 24: 827–839.
29. Satyamoorthy K, Chhabh NH, Waterman MJ, Lien MC, El-Deiry WS, et al. (2010) Abrant activation function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ 11: 467–474.
30. Kastan MB, Berkoewicz E (2007) p53: a two-faced cancer gene. Nat Cell Biol 9: 489–491.
31. Wexl L, Damalas A, Lontos M, Karakaidos P, Fotennaghi G, et al. (2007) Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 67: 2396–2401.
32. Dickopp A, Esche H, Swart G, Seeler S, Kirk HC, et al. (2000) Transformation-defective adenovirus 5 EIA mutants exhibit antigenic properties in human BLM melanoma cells. Cancer Gene Ther 7: 1043–1050.
33. Baldker ABH, Phillips JH, Figdor CG, Lanier LL (1998) Killer Cell Inhibitory Receptors for MHC Class I Molecules Regulate Lysis of Melanoma Cells Mediated by NK cells. (gamma)[delta] T Cells, and Antigen-Specific CTL. J Immunol 160: 5239–5245.
34. Van Muijen GN, Cornelissen LM, Janssen CF, Figdor CG, Johnson JP, et al. (1991) Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis 9: 259–272.
35. Riebeling C, Muller C, Gelten CC (2003) Expression and regulation of phospholipase D inoezymes in human melanoma cells and primary melanocytes. Melanoma Research 13.
36. Lehmann JM, Riedhammer G, Johnson JP (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 86: 9891–9895.
37. Solit DB, Garraway LA, Pratillas CA, Saiwai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 355–362.
38. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, et al. (1999) Identification of New HER2/Neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogeneic Carcinomas and Melanomas. J Immunol 163: 1037–1044.
39. Becker JC, Dummer R, Hartmann AA, Burg G, Schmidt RE (1991) Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell- mediated cytotoxicity. J Immunol 147: 4398–4406.
40. Haftekamp S, Scurl LL, Becker TM, Frausto M, Keeford RF, et al. (2009) Oncogene-induced senescence does not require the p16INK4a or p14ARF melanoma tumor suppressors. J Invest Dermatol 129: 1983–1991.
41. Verhaegen M, Bauer JA, Martin di V, Wang G, Wolter KG, et al. (2006) A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66: 11348–11359.
42. Smith SL, Shoda T (2009) Advantages of COS-1 monkey kidney epithelial cells as packaging host for small-volume production of high-quality recombinant lentiviruses. Journal of Virological Methods 157: 47–54.
43. Wichhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M (2003) CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22: 8233–8245.

Author Contributions

Conceived and designed the experiments: RH JW JCB. Performed the experiments: RH SHaferkamp CPS UF CSK CSLM SHebacher. Analyzed the data: RH CSLM CSK JCB. Contributed reagents/materials/analysis tools: JCB. Wrote the paper: RH DS JW JCB.